An observational study in Lung Cancer (Diagnosis) and Nodule, Solitary Pulmonary, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Herlev and Gentofte Hospital · Observational
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.
Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Lung nodules are frequent findings on chest CT scans. The majority of nodules are benign, but a substantial fraction will be malignant. The decision to pursue invasive diagnostics currently rely on a risk estimate based on patient characteristics and radiological features of the nodule.
Accurate risk estimation is crucial as invasive diagnostics comes with a significant risk of severe complications such as collapsed lung, bleeding, infections and in rare cases death. The NIMBLE project seeks to improve the early risk assessment by incorporation of blood biomarkers in the risk algorithm. The study will include 1,200 patients with a nodule when patients are referred to the dept. of pulmonology and perform an addition blood draw. The blood will be analyzed using a wide range of blood tests. These will include standard blood tests, novel protein tumor markers specifically targeting lung cancer, an epigenetic smoking marker (AHRR methylation), and combined fragmentome, mutational and methylome analysis of cell-free tumor DNA.
Blood tests will be evaluated following REMARK guidelines in terms of lung cancer predictive performance but also in terms of feasibility in implementation in daily routine testing at a Dept. of Clinical Biochemistry.
The study will perform all tests on patient material collected at baseline when patients are referred to work-up and use machine learning to optimally combine blood tests with patient characteristics and radiological features.
5,422 studies on the registry are indexed under Lung Neoplasms; 1,346 are open to participants now.
This study's planned enrollment of 1,800 is above the median of 200 across 1,434 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Herlev and Gentofte Hospital is the lead sponsor of 75 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients referred to the infiltrate unit at the Dept. of Pulmonology, Gentofte Hospital, Denmark
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients are enrolled when these are referred to the Pulmonology Department suspected of lung cancer.
Diagnostic Test: Blood tests
Standard blood tests, Novel protein tumor markers specifically targeting lung cancer, Epigenetic smoking marker (AHRR methylation), Combined fragmentome, mutational and methylome analysis of cell-free tumor DNA
Lung cancer diagnosis during work-up
Time frame: At least two years of followup
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Feb 2028, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Herlev and Gentofte Hospital